FAB Pharma’s approach consists in developing a new class of low-molecular-weight antibacterial molecules which target a specific, essential enzyme in MRSA called Fatty Acid Biosynthesis I (FAB I).
FAB Pharma completed a €2.3m round of series A funding led by CDC innovation and co-led by Bioam Gestion.
FAB Pharma is a corporate spin-out from Paris-based Mutabilis. The new biopharmaceutical company is focused on the discovery and development of therapeutics that will address today’s antibiotic resistance issues and control severe bacterial infections.
The funds will be used to finance Phase I clinical trials and develop back-up products.